Neurocrine Biosciences (NBIX) total liabilities

Total liabilities · fiscal 2025
$1.38B

Neurocrine Biosciences (NBIX) had total liabilities of $1.38B at the end of fiscal 2025 (December 31, 2025). That is 22.1% higher than the $1.13B of fiscal 2024. Figures as of 19 Nov 2026, 01:56 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$1.38B
Change on fiscal 2024
+22.1%
Growth, 5 years
+17.8% a year
Growth, 10 years
+39.2% a year
Highest on record
$1.38Bfiscal 2025
Lowest on record
$34.27Mfiscal 2013
Fiscal years on record
162010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Neurocrine Biosciences total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 17.8% a year; over ten years the rate was 39.2% a year. Across the 16 fiscal years on record (2010–2025), the highest was $1.38B in fiscal 2025 and the lowest $34.27M in fiscal 2013.

History · 16 fiscal years

Total liabilities by fiscal year

Neurocrine Biosciences total liabilities, year by year

Neurocrine Biosciences (NBIX) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$1.38B 22.1% up
2024$1.13B 10.8% up
2023$1.02B 54.2% up
2022$660.90M 5.4% down
2021$698.50M 14.8% up
2020$608.50M 9.1% down
2019$669.10M 30.6% up
2018$512.39M 15.0% up
2017$445.45M 787.2% up
2016$50.21M 0.2% down
2015$50.33M 46.6% up
2014$34.33M 0.2% up
2013$34.27M 17.6% down
2012$41.61M 46.9% down
2011$78.29M 37.4% down
2010$125.08M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Neurocrine Biosciences and comparable companies
CompanyTotal liabilitiesFiscal year
Revvity RVTY$4.92B2025
Exelixis EXEL$683.10M2025
Charles River Laboratories International CRL$3.92B2025
Neurocrine Biosciences NBIX$1.38B2025
Ascendis Pharma ASND€1.47B2025
ICON ICLR$7.08B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on NBIX

Neurocrine Biosciences, figure by figure

Neurocrine Biosciences (NBIX) overview: price, valuation and scorecardAll health care companies by market value

Neurocrine Biosciences total liabilities: questions and answers

How large are Neurocrine Biosciences's total liabilities?

Neurocrine Biosciences (NBIX) had total liabilities of $1.38B at the end of fiscal 2025 (December 31, 2025). That is 22.1% higher than the $1.13B of fiscal 2024.

What is the growth rate of Neurocrine Biosciences's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 17.8% a year; over ten years the rate was 39.2% a year.

What are the highest and lowest total liabilities figures on record for Neurocrine Biosciences?

Across the 16 fiscal years on record (2010–2025), the highest was $1.38B in fiscal 2025 and the lowest $34.27M in fiscal 2013.

How is Neurocrine Biosciences's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Neurocrine Biosciences it is on record here for 16 fiscal years, 2010 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Neurocrine Biosciences (NBIX) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/NBIX/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.